A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY
Back
Abstract Number
WCN23-1085
Categories
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Other CKD
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY
Co-authors
Lambers Heerspink, H.(1)*;Jardine, M.(2);Kohan, D.E.(3);Lafayette, R.(4);Levin, A.(5);Liew, A.(6);Zhang, H.(7);Sheth, K.(8);Camargo, M.(8);Jones-Burton, C.(8);King, A.J.(9);Barratt, J.(10);
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)University Of Groningen, Department Of Clinical Pharmacy And Pharmacology, Groningen, Netherlands;(2)University Of Sydney, Nhmrc Clinical Trials Centre, Sydney, Australia;(3)University Of Utah, Division Of Nephrology, Salt Lake City, United States;(4)Stanford University, Division Of Nephrology, Stanford, United States;(5)The University Of British Columbia, Division Of Nephrology, Vancouver, Canada;(6)Mount Elizabeth Novena Hospital, Renal Medicine, Singapore, Singapore;(7)Peking University First Hospital, Renal Division, Bejing, China;(8)Chinook Therapeutics- Inc, Clinical Development, Seattle, United States;(9)Chinook Therapeutics- Inc, Biology, Seattle, United States;(10)University Hospitals Of Leicester, Renal Medicine, Leicester, United Kingdom;
E-Poster
https://storage.unitedwebnetwork.com/files/1/213a61bc84dbefdbc73c57b4e3f6d2d9.pdf
Audio File
if any